Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterActive in the last 2 years

Sanjay S. Reddy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9306-2574; OpenAlex author ID A5001339565. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 3, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers, 1 trial · 2022: 5 papers · 2023: none · 2024: 2 papers · 2025: 2 papers

Papers 15

  1. Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01188-x↗
  2. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. Co-author DOI 10.1089/jpm.2024.0313↗
  3. Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.amjsurg.2023.10.053↗
  4. Smoking history is associated with reduced efficacy of neoadjuvant therapy in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gassur.2024.01.007↗
  5. Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma. Last author DOI 10.1002/jso.26906↗
  6. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Last author DOI 10.1016/j.ejso.2021.12.473↗
  7. Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio. Last author DOI 10.1016/j.jss.2022.08.002↗
  8. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-021-10219-3↗
  9. ASO Author Reflections: Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-021-10230-8↗
  10. Predicting positive peritoneal cytology in pancreatic cancer. Last author DOI 10.1007/s00432-020-03471-9↗
  11. Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? Last author DOI 10.5306/wjco.v12.i2.54↗
  12. Biliary microbiome in pancreatic cancer: alterations with neoadjuvant therapy. Co-author DOI 10.1016/j.hpb.2019.04.005↗
  13. The Utility of Preoperative Vascular Grading in Patients Undergoing Surgery First for Pancreatic Cancer: Does Radiologic Arterial or Venous Involvement Predict… Last author DOI 10.1155/2018/7675262↗
  14. Randomized Clinical Trials in Pancreatic Cancer. First author DOI 10.1016/j.soc.2017.05.005↗
  15. Is It Time for Total Neoadjuvant Therapy for Patients With Resectable Pancreatic Adenocarcinoma? First author DOI 10.1200/jop.2016.016352↗

Trials 1

  1. PHL Treatment in Pancreatic Cancer Principal investigator NCT05365893↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joshua E. Meyer · 6 shared papers, 2021–2025 · strength 1.25
  2. Dany Barrak · 5 shared papers, 2022–2024 · strength 1.01
  3. Anthony M. Villano · 5 shared papers, 2022–2024 · strength 1.01
  4. Efrat Dotan · 4 shared papers, 2021–2025 · strength 0.73
  5. Neha Goel · 4 shared papers, 2017–2022 · strength 0.53
  6. Rita C. Akumuo · 2 shared papers, 2024 · strength 0.50
  7. John Parker Hoffman · 4 shared papers, 2016–2022 · strength 0.48
  8. Shannon M. Lynch · 2 shared papers, 2025 · strength 0.44
  9. Maitham A. Moslim · 2 shared papers, 2021–2022 · strength 0.37
  10. Eileen A. O’Halloran · 2 shared papers, 2021–2022 · strength 0.32
  11. Jenny A. O'Brien · 1 shared paper, 2025 · strength 0.23
  12. Namrata Vijayvergia · 1 shared paper, 2025 · strength 0.21
  13. Lauren Laderman · 1 shared paper, 2025 · strength 0.21
  14. Anush Narasimhan Sridharan · 1 shared paper, 2025 · strength 0.21
  15. Edna Cukierman · 1 shared paper, 2025 · strength 0.21
  16. Igor A. Astsaturov · 1 shared paper, 2025 · strength 0.21
  17. Michael J. Hall · 1 shared paper, 2021 · strength 0.19
  18. Eddie Zhang · 1 shared paper, 2022 · strength 0.15
  19. Talha Shaikh · 1 shared paper, 2022 · strength 0.15
  20. Steven J. Cohen · 1 shared paper, 2022 · strength 0.15
  21. Henry Anthony Pitt · 1 shared paper, 2019 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.